Arimoclomol - Orphazyme

Drug Profile

Arimoclomol - Orphazyme

Alternative Names: BRX-345; OR-01; OR-04; Orphazyme OR-01

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biorex
  • Developer CytRx Corporation; Food and Drug Administration; Orphazyme; University of Kansas Medical Center
  • Class Hydroxylamines; Small molecules
  • Mechanism of Action Molecular chaperone modulators; Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick diseases; Amyotrophic lateral sclerosis; Inclusion body myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis; Niemann-Pick diseases
  • Phase II/III Inclusion body myositis
  • Phase II Gaucher's disease
  • No development reported Glioblastoma

Most Recent Events

  • 28 Sep 2018 Top-line safety and efficacy data from a phase II/III trial in Niemann-Pick disease released by Orphzyme
  • 13 Sep 2018 Orphazyme intends to submit MAA and NDA to EMA and US FDA, respectively, for Niemann-Pick disease in the second half of 2019
  • 13 Sep 2018 Orphazyme plans to launch arimoclomol for Niemann-Pick disease in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top